Health Discovery Corporation Announces Successful Clinical Trial Results For New Molecular Diagnostic Test For Prostate Cancer

Health Discovery Corporation (”HDC”) (OTCBB: HDVY) announced the successful clinical trial results for HDC’s new molecular diagnostic test for prostate cancer licensed exclusively to Clarient (Nasdaq:CLRT), in which HDC will receive a 30 percent royalty based on reimbursements received by Clarient from third parties.

More: continued here

Filed under: Prostate on May 15th, 2008